Physician profile
Weiquan Lu
NPI 1275722456
$1,941.52
in general payments reported to CMS, 2019-2025
19 companies · $479 in 2025
The $479 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2021: $23.53 · 2022: $220 · 2023: $454 · 2024: $106 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $899 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.64 |
| Education | $139.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $221.83 | 2022-2023 | Tukysa |
| Celgene Corporation | $205.95 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $200.03 | 2019-2023 | Opdivo |
| Abbvie INC. | $200.02 | 2019-2022 | |
| Incyte Corporation | $161.01 | 2024-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $141.96 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $132.39 | 2019-2024 | Keytruda |
| Lilly USA, LLC | $124.85 | 2023 | |
| Pharmacosmos Therapeutics INC. | $121.83 | 2025 | Cosela |
| Alexion Pharmaceuticals, INC. | $120.80 | 2019 | |
| Karyopharm Therapeutics INC. | $79.04 | 2025 | Xpovio |
| Astellas Pharma US INC | $74.99 | 2025 | |
| Caris Mpi, INC. | $64.54 | 2025 | Mi Cancer Seek |
| Eisai INC. | $19.75 | 2022 | |
| Janssen Biotech, INC. | $18.23 | 2025 | Talvey, Darzalex |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.54 | 2019 | |
| Sobi, INC | $15.23 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Jazz Pharmaceuticals INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiquan Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.